drugset
drugset / Trial / NCT02727998

Intensive 7-day Treatment for PTSD Combining Ketamine With Exposure Therapy

NCT02727998 ↗

Phase 2 Terminated 28 enrolled Yale University
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to combine a single infusion of Ketamine with 7-days of trauma focus psychotherapy to relieve post traumatic stress disorder (PTSD) symptoms more effectively. This treatment has the potential to produce a significant therapeutic effect that otherwise would take months to occur.

Timeline

Start
2015-12
Primary completion
2021-11-28
Completion
2021-11-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketamine Small molecule 0.5 mg/kg —
Comparator Midazolam Small molecule 0.045 mg/kg —

Indications

post-traumatic stress disorder